Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM2002 in CABG for Ischemic Heart Failure
NCT06621576Phase 1Completed
- Sponsor
- Ruijin Hospital
- Start
- Sep 2024
- Primary completion
- May 2025
- Modality
- Long Non-coding RNA (lncRNA)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HM2002 in Ischemic Heart Failure (IHF), sponsored by Ruijin Hospital. Primary endpoint: Adverse Events at 6 months. Started Sep 2024; status: completed.
02
Drugs
HM2002
03
Conditions
Ischemic Heart Failure (IHF)
Beyond the preview
Go deeper on NCT06621576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06621576.